|
|
Volumn 380, Issue 9839, 2012, Pages 325-
|
|
FDA paves the way for pre-exposure HIV prophylaxis
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
PLACEBO;
ADENINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIVIRUS AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
EMTRICITABINE;
ORGANOPHOSPHORUS COMPOUND;
PHOSPHONIC ACID DERIVATIVE;
TENOFOVIR;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CIRCUMCISION;
CONDOM;
DRUG EFFICACY;
FOOD AND DRUG ADMINISTRATION;
GEL;
HEALTH CARE COST;
HEALTH CARE POLICY;
HIGH RISK BEHAVIOR;
HIGH RISK POPULATION;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFECTION PREVENTION;
MALE HOMOSEXUAL;
NOTE;
PRIORITY JOURNAL;
SEXUAL TRANSMISSION;
TRANSSEXUALISM;
VIRUS TRANSMISSION;
DISEASE TRANSMISSION;
DRUG COMBINATION;
LEGAL ASPECT;
METHODOLOGY;
PRIMARY PREVENTION;
UNITED STATES;
ADENINE;
ANTI-HIV AGENTS;
ANTIVIRAL AGENTS;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
HIV INFECTIONS;
HUMANS;
ORGANOPHOSPHORUS COMPOUNDS;
PHOSPHONIC ACIDS;
PRIMARY PREVENTION;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84864186938
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(12)61235-5 Document Type: Note |
|
Times cited : (54)
|
|
References (0)
|
